Evidence map›Paper›PMID 29593529›Full record

ArticleFrontiers in pharmacology2018

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in

Behzad Bidadi, Duan Liu, Krishna R Kalari, Matthias Rubner, Alexander Hein, Matthias W Beckmann, Brigitte Rack, Wolfgang Janni, Peter A Fasching, Richard M Weinshilboum and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. International journal of molecular sciences · 2020
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Behzad BidadiDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
Duan LiuDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
Krishna R KalariDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
Matthias RubnerDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Alexander HeinDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Brigitte RackDepartment of Gynecology and Obstetrics, Ludwig-Maximilians-Universität München, Munich, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Richard M WeinshilboumDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
Liewei WangDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
Mayo Clinic · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversitätsklinikum Erlangen · DELudwig-Maximilians-Universität München · DEMayo Clinic in Florida · USUniversity Hospital Ulm · DE

Funding

Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
TRAINING GRANT IN CLINICAL PHARMACOLOGYT32GM008685 · NIGMS · MAYO CLINIC ROCHESTER · PI Liewei Wang · 1998 to 2026
$8.2M
Pharmacogenomics of Breast Cancer Adjuvant ChemotherapyU01HG005137 · NHGRI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2009 to 2011
$2.1M
NHGRI NIH HHS U01 HG005137NIGMS NIH HHS T32 GM008685NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

Neutropenia secondary to chemotherapy in breast cancer patients can be life-threatening and there are no biomarkers available to predict the risk of drug-induced neutropenia in those patients. We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast cancer who were treated with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-A trial. A genome-wide significant single-nucleotide polymorphism (SNP) signal in the tumor necrosis factor superfamily member 13B (

Indexed as

breast cancerGWASHMMRneutropeniaTNFSF13B

Identifiers

PMID29593529
PMCPMC5859084
OpenAlexW2794331781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.